Prognostic indicators for AIDS and infectious disease death in HIV- infected injection drug users: Plasma viral load and CD4+ cell count

JAMA

Volumn 279, Issue 1, 1998, Pages 35-40

  Vlahov, David ^a   Graham, Neil ^a   Hoover, Donald ^a   Flynn, Colin ^a   Bartlett, John G ^b   Margolick, Joseph B ^a   Lyles, Cynthia M ^a   Nelson, Kenrad E ^a   Smith, Dawn ^c   Holmberg, Scott ^c   Farzadegan, Homayoon ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE COURSE; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROGNOSIS; VIRUS LOAD;

EID: 0010240431     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.1.35     Document Type: Article

References (30)

1. + T-cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med. 1990;113:438-443.
2. Escaich S, Ritter J, Rougier P, et al. Relevance of the quantitative detection of HIV proviral sequences in PBMC of infected individuals. AIDS Res Hum Retroviruses. 1992;8:1833-1837.
3. Yerly S, Chamot E, Hirschel B, Perrin LH. Quantitation of human immunodeficiency provirus and circulating virus: relationship with immunologic parameters. J Infect Dis. 1992;166:269-276.
4. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol. 1993;67:1772-1777.
5. Farzadegan H, Levy D, Astemborski J, Saah AJ, Vlahov D, Graham NMH. The effect of gender, race, injecting drug use, and disease stage on infectious HIV-1 viral burden among IDUs and gay men. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract We.C.3418.
6. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994;32:292-300.
7. + lymphocytes. Proc Natl Acad Sci U S A 1994;91:1104-1108.
8. Holodniy M, Katzenstein D, Winters M, et al. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J Acquir Immune Defic Syndr. 1993;6:366-369.
9. Mellors J, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-579.
10. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
11. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
12. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996;334:426-431.
13. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside analogue therapy in HIV-infected adulte with 200 to 500 CD4 cells per cubic millimeter: AIDS Clinical Trials Group Study 175 Virologic Study. N Engl J Med. 1996;335:1091-1098.
14. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105-110.
15. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1989;38:1-9.
16. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-949.
17. Vlahov D, Anthony JC, Muñoz A, et al. The ALIVE study: a longitudinal study of HIV-1 infection among intravenous drug users: description of methods. J Drug Issues. 1991;21:767-779.
18. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:RR-17.
19. Hoffman RA, Kunge PC, Hansen WP, et al. Simple and rapid measurement of human T-lymphocytes and their subclasses in peripheral blood. Proc Natl Acad Sci U S A. 1980;77:4914-4917.
20. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort experience. Clin Immunol Immunopathol. 1990;55:173-186.
21. Manoff SB, Vlahov D, Herskowitz A, et al. Human immunodeficiency virus infection and infective endocarditis among injecting drug users. Epidemiology. 1996;7:566-570.
22. Caiaffa WT, Vlahov D, Graham NMH, et al. Drug smoking, Pneumocystis carinii pneumonia and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-sero-positive injection drug users. Am J Respir Crit Care Med. 1994;150:1493-1498.
23. Cox DR, Oakes O. Analysis of Survival Data. London, England: Chapman & Hall; 1984.
24. Chaisson RE, Fuehs E, Stanton D, et al. Racial heterogeneity of HIV antigenemia in persons with HIV infection. AIDS. 1991;5:177-180.
25. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus, type 1. N Engl J Med. 1990;332:166-172.
26. Muñoz A, Vlahov D, Solomon L, et al. Prognostic indicators for development of AIDS among intravenous drug users. J Acquir Immune Defic Syndr. 1992;5:694-700.
27. Solomon L, Vlahov D, Astemborski J, Galai N, Graham NMH, Nelson KE. Factors associated with initiation of zidovudine in a cohort of injection drug users. J Drug Issues. 1995;25:225-233.
28. Hoover DR. The effects of long-term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. Drugs. 1995;49:20-36.
29. Holodniy M, Mole L, Yen-Lieberman B, et al. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in vacutainer CPT, vacutainer PPT, and standard vacutainer tubes. J Clin Microbiol. 1995;33:1562-1566.
30. Harrison K, Vlahov D, Jones K, Charron K, Clements ML. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:386-390.